Fusion Pharmaceuticals (FUSN)
(Delayed Data from NSDQ)
$21.52 USD
+0.05 (0.23%)
Updated May 31, 2024 04:00 PM ET
After-Market: $21.54 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
FUSN 21.52 +0.05(0.23%)
Will FUSN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for FUSN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FUSN
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
FUSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Other News for FUSN
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Ontario court approves AstraZeneca/Fusion acquisition plan
Fusion Pharmaceuticals receives final court order approving AstraZeneca deal
Fusion Pharmaceuticals Shareholders Back Major AstraZenica Deal
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca